Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 6,275 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Steroid Clear all

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Plasma Cell Myeloma
Interventions: Bortezomib, Daratumumab, Dexamethasone, Iberdomide; Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Allergic Rhinitis
Interventions: fluticasone furoate, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Vitamin D Deficiency
Interventions: Vitamin D; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Female only
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Hematological Malignancies
Interventions: Cyclophosphamide, Thiotepa, Fludarabine, Melphalan, Mesna, G-CSF, Mycophenolate mofetil, Tacrolimus, Methylprednisolone, Total lymphoid irradiation, Lymphocyte infusions, CliniMACS; Drug · Biological · Radiation + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Graft-versus-Host Disease
Interventions: Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Female Breast Cancer
Interventions: Estradiol; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Anxiety
Interventions: HPA, ANS stimulation, Placebo; Drug
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cranial Nerve Disorder, Head and Neck Carcinoma, Oropharyngeal Carcinoma
Interventions: Methylprednisolone, Prednisone, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Interventions: tucatinib, trastuzumab, fulvestrant; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 76
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more

Conditions: Hypogonadotropic Hypogonadism, Kallmann Syndrome
Interventions: Anastrozole Pill, Testosterone, Placebo Oral Tablet; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions: Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol; Drug · Biological · Radiation + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, keyhole limpet hemocyanin, sargramostim, cyclophosphamide, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Genitope Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 21
States / cities: Dublin, California • Greenbrae, California • Los Angeles, California + 16 more

Conditions: Menorrhagia
Interventions: Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 37
States / cities: Tucson, Arizona • Beverly Hills, California • Carmichael, California + 32 more

Conditions: Multiple Myeloma
Interventions: Daratumumab, Lenalidomide, Bortezomib, Dexamethasone; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Detroit, Michigan • Rochester, New York + 1 more

Conditions: Cataract
Interventions: Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}, Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}; Drug
Lead sponsor: Inder Paul Singh, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Venice, Florida • Racine, Wisconsin

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Palonosetron, ondansetron, Dexamethasone; Drug
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years to 85 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Cyclophosphamide, Dexamethasone; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Palm Springs, California • Worcester, Massachusetts + 2 more

Conditions: Vitamin D Deficiency
Interventions: cholecalciferol (vitamin D3), cholecalciferol; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 501 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chronic Graft-versus-host-disease
Interventions: INCA034176, Placebo, Corticosteroids; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 32 more

Conditions: Asthma
Interventions: beclomethasone, fluticasone; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature, Bronchopulmonary Dysplasia
Interventions: Hydrocortisone, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 30 Weeks
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Multiple Sclerosis, Relapsing-remitting
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: San Francisco, California • Baltimore, Maryland

Search by objective public record fields.

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

Personalized Vitamin D Supplementation in European and African Americans

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

Estrogen for Triple Negative Breast Cancer

Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response

High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma

Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC

Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients

A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma

Evaluation of Vitamin D Requirements During Pregnancy

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma

Hydrocortisone for BPD

Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health